[Evaluation of serum sICAM-1 amd CA-125 in patients with ovarian tumors--preliminary report].
OBJECTIVE
Today's diagnostics and differentiation of ovarian tumour is not efficient enough. Wide spreading tumour immunology of neoplasm presents an opportunity to determine new markers and mechanisms useful for diagnostic and discrimination. The aim of our study was to evaluate concentration of soluble intracellular adhesion molecule-1 (sICAM-1) with CA-125 in ovarian cancer.


METHODS
Serum of 40 patients undergoing surgical treatment, 32 with ovarian cancer and 8 with benign tumours. Concentration of markers was determined immunoenzymatically.


RESULTS
Concentration of sICAM-1 correlated moderately with FIGO stage, tumour volume and CA-125. Mean concentrations between analysed groups were different, but not statistically significant. Determination of sICAM-1 together with CA-125 increased discrimination power of the test.


CONCLUSIONS
Determination of sICAM-1 alone seems to have limited application. Addition of this test to CA-125 could improve value of the diagnostic process.
Katedry i Kliniki Zdrowia Matki i Dziecka AM w Poznaniu.
Paweł
P
Rzymski
Jakub
J
Woźniak
Tomasz
T
Opala
Stefan
S
Sajdak
Krzysztof
K
Drews
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood*; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000601:surgery; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D018799:Intercellular Adhesion Molecule-1